Risk factors for imipenem-nonsusceptible Acinetobacter nosocomialis bloodstream infection

Journal of Microbiology, Immunology and Infection

Volumn 47, Issue 4, 2014, Pages 311-317

  Huang, Lei ^a,b   Chen, Te Li ^a,c   Lee, Yi Tzu ^a,c,d   Lee, Mei Hui ^a   Kuo, Shu Chen ^a,c,e   Yu, Kwok Woon ^a   Dou, Horng Yunn ^e   Fung, Chang Phone ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b LOTUNG POH AI HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d Chutung Veterans Hospital   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Acinetobacter nosocomialis; Bacteremia; Imipenem resistance; Risk factors

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DNA 16S; DNA 23S; GENTAMICIN; IMIPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; SPACER DNA; SULBACTAM; SULTAMICILLIN;

ACINETOBACTER; ACINETOBACTER NOSOCOMIALIS; ADULT; AGED; ALCOHOLISM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; APACHE; ARTERY CATHETERIZATION; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CHEMOTHERAPY; CHRONIC LUNG DISEASE; END STAGE RENAL DISEASE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR; SEQUENCE ANALYSIS; TAIWAN; TERTIARY CARE CENTER; TOTAL PARENTERAL NUTRITION; ACINETOBACTER INFECTIONS; ANTIBIOTIC RESISTANCE; CROSS INFECTION; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; RISK; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; ACINETOBACTER; ACINETOBACTER INFECTIONS; AGED; AGED, 80 AND OVER; BACTEREMIA; BETA-LACTAM RESISTANCE; CROSS INFECTION; FEMALE; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84904498719     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2013.02.002     Document Type: Article

References (32)

1. Kempf M., Rolain J.M. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012, 39:105-114.
2. Lee J.H., Choi C.H., Kang H.Y., Lee J.Y., Kim J., Lee Y.C., et al. Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU. J Antimicrob Chemother 2007, 59:633-639.
3. Gootz T.D., Marra A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect Ther 2008, 6:309-325.
4. Poirel L., Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006, 12:826-836.
5. Unal S., Garcia-Rodriguez J.A. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005, 53:265-271.
6. Mendes R.E., Bell J.M., Turnidge J.D., Castanheira M., Jones R.N. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 2009, 63:55-59.
7. Nosocomial Infections Surveillance System [Internet]. 2010 Statistics of Communicable Diseases and Surveillance Report. Available from: [accessed 07.12]. http://www2.cdc.gov.tw/ct.asp%3fxItem%3d7773%26ctNode%3d948%26mp%3d5.
8. Sunenshine R.H., Wright M.O., Maragakis L.L., Harris A.D., Song X., Hebden J., et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13:97-103.
9. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002, 23:106-108.
10. Sheng W.H., Liao C.H., Lauderdale T.L., Ko W.C., Chen Y.S., Liu J.W., et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 2010, 14:e764-e769.
11. Playford E.G., Craig J.C., Iredell J.R. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. JHosp Infect 2007, 65:204-211.
12. Spence R.P., Towner K.J., Henwood C.J., James D., Woodford N., Livermore D.M. Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK. J Med Microbiol 2002, 51:1107-1112.
13. Routsi C., Pratikaki M., Platsouka E., Sotiropoulou C., Nanas S., Markaki V., et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010, 38:173-180.
14. Le Hello S., Falcot V., Lacassin F., Mikulski M., Baumann F. Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific. Scand J Infect Dis 2010, 42:821-826.
15. Chen T.L., Siu L.K., Wu R.C., Shaio M.F., Huang L.Y., Fung C.P., et al. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect 2007, 13:801-806.
16. Chang H.C., Wei Y.F., Dijkshoorn L., Vaneechoutte M., Tang C.T., Chang T.C. Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. JClin Microbiol 2005, 43:1632-1639.
17. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988, 16:128-140.
18. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement 2011, Clinical and Laboratory Standards Institute, CLSI Document M100-S21, CLSI, Wayne, PA.
19. Baran G., Erbay A., Bodur H., Onguru P., Akinci E., Balaban N., et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008, 12:16-21.
20. Huang S.T., Chiang M.C., Kuo S.C., Lee Y.T., Chiang T.H., Yang S.P., et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. JMicrobiol Immunol Infect 2012, 45:356-362.
21. Smolyakov R., Borer A., Riesenberg K., Schlaeffer F., Alkan M., Porath A., et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003, 54:32-38.
22. Nseir S., Di Pompeo C., Cavestri B., Jozefowicz E., Nyunga M., Soubrier S., et al. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: prevalence, risk factors, and outcome. Crit Care Med 2006, 34:2959-2966.
23. Cisneros J.M., Rodriguez-Bano J., Fernandez-Cuenca F., Ribera A., Vila J., Pascual A., et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect 2005, 11:874-879.
24. Mahgoub S., Ahmed J., Glatt A.E. Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. Am J Infect Control 2002, 30:386-390.
25. Shih M.J., Lee N.Y., Lee H.C., Chang C.M., Wu C.J., Chen P.L., et al. Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study. J Microbiol Immunol Infect 2008, 41:118-123.
26. Jamulitrat S., Thongpiyapoom S., Suwalak N. An outbreak of imipenem-resistant Acinetobacter baumannii at Songklanagarind Hospital: the risk factors and patient prognosis. J Med Assoc Thai 2007, 90:2181-2191.
27. Liang-Yu C., Kuo S.C., Liu C.Y., Luo B.S., Huang L.J., Lee Y.T., et al. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997-2007. J Microbiol Immunol Infect 2011, 44:358-363.
28. Lee Y.T., Kuo S.C., Chiang M.C., Yang S.P., Chen C.P., Chen T.L., et al. Emergence of carbapenem-resistant non-baumannii species of Acinetobacter harboring a blaOXA-51-like gene that is intrinsic to A. baumannii. Antimicrob Agents Chemother 2012, 56:1124-1127.
29. Opazo A., Sonnevend A., Lopes B., Hamouda A., Ghazawi A., Pal T., et al. Plasmid-encoded PER-7 β-lactamase responsible for ceftazidime resistance in Acinetobacter baumannii isolated in the United Arab Emirates. J Antimicrob Chemother 2012, 67:1619-1622.
30. Nigro S.J., Farrugia D.N., Paulsen I.T., Hall R.M. A novel family of genomic resistance islands, AbGRI2, contributing to aminoglycoside resistance in Acinetobacter baumannii isolates belonging to global clone. J Antimicrob Chemother 2013, 68:554-557.
31. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21:538-582.
32. Liu Y.H., Kuo S.C., Lee Y.T., Chang I.C., Yang S.P., Chen T.L., et al. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU. J Microbiol Immunol Infect 2012, 45:108-112.